Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Keating, MJ' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 167 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Ferrajoli, A; Manshouri, T; Estrov, Z; Keating, MJ; O'Brien, S; Lerner, S; Beran, M; Kantarjian, HM; Freireich, EJ; Albitar, M
      High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia

      CLINICAL CANCER RESEARCH
    2. Yamauchi, T; Nowak, BJ; Keating, MJ; Plunkett, W
      DNA repair initiated in chronic. lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine

      CLINICAL CANCER RESEARCH
    3. Aboul-Nasr, R; O'Brien, S; Freireich, EJ; Ginsberg, CF; Kantarjian, HM; Koller, CA; Keating, MJ; Albitar, M
      "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow

      LEUKEMIA & LYMPHOMA
    4. Dabaja, BS; O'Brien, SM; Kantarjian, HM; Cortes, JE; Thomas, DA; Albitar, M; Schlette, ES; Faderl, S; Sarris, A; Keating, MJ; Giles, FJ
      Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome

      LEUKEMIA & LYMPHOMA
    5. Giles, FJ; Shen, Y; Kantarjian, HM; Korbling, MJ; O'Brien, S; Anderlini, P; Donato, M; Pierce, S; Keating, MJ; Freireich, EJ; Estey, E
      Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival

      LEUKEMIA & LYMPHOMA
    6. Di Raimondo, F; Giustolisi, R; Lerner, S; Cacciola, E; O'Brien, S; Kantarjian, H; Keating, MJ
      Retrospective study of the prognostic role of serum thymidine kinase levelin CLL patients with active disease treated with fludarabine

      ANNALS OF ONCOLOGY
    7. Gandhi, V; Plunkett, W; Weller, S; Du, M; Ayres, M; Rodriguez, CO; Ramakrishna, P; Rosner, GL; Hodge, JP; O'Brien, S; Keating, MJ
      Evaluation of the combination of nelarabine and fludarabine in leukemias: Clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells

      JOURNAL OF CLINICAL ONCOLOGY
    8. O'Brien, SM; Kantarjian, H; Thomas, DA; Giles, FJ; Freireich, EJ; Cortes, J; Lerner, S; Keating, MJ
      Rituximab dose-escalation trial in chronic lymphocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    9. Bullrich, F; Fujii, H; Calin, G; Mabuchi, H; Negrini, M; Pekarsky, Y; Rassenti, L; Alder, H; Reed, JC; Keating, MJ; Kipps, TJ; Croce, CM
      Characterization of the 13q14 tumor suppressor locus in CLL: Identification of ALT1, an alternative splice variant of the LEU2 gene

      CANCER RESEARCH
    10. Fayad, L; Keating, MJ; Reuben, JM; O'Brien, S; Lee, BN; Lerner, S; Kurzrock, R
      Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

      BLOOD
    11. Huh, YO; Keating, MJ; Saffer, HL; Jilani, I; Lerner, S; Albitar, M
      Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia

      AJCP. American journal of clinical pathology
    12. Estey, E; Cortes, J; Beran, M; Koller, CA; Keating, MJ
      AML in the elderly

      ACUTE LEUKEMIAS VIII: PROGNOSTIC FACTORS AND TREATMENT STRATEGIES
    13. Rodriguez, CO; Plunkett, W; Paff, MT; Du, M; Nowak, B; Ramakrishna, P; Keating, MJ; Gandhi, V
      High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells

      JOURNAL OF CHROMATOGRAPHY B
    14. Saad, ED; Thomas, DA; O'Brien, S; Fuller, GN; Medeiros, LJ; Forman, A; Albitar, M; Schomer, D; Kantarjian, HM; Keating, MJ
      Progressive multifocal leukoencephalopathy with concurrent Richter's syndrome

      LEUKEMIA & LYMPHOMA
    15. Keating, MJ; Smith, TL; Lerner, S; O'Brien, S; Robertson, LE; Kantarjian, H; Freireich, EJ
      Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia

      LEUKEMIA & LYMPHOMA
    16. Giles, FJ; Wong, GC; Clark, SJ; Pierce, S; Kantarjian, HM; Keating, MJ
      Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia

      LEUKEMIA & LYMPHOMA
    17. D'Arena, G; Keating, MJ; Carotenuto, M
      Chronic lymphoproliferative disorders: An integrated point of view for thedifferential diagnosis

      LEUKEMIA & LYMPHOMA
    18. Haidar, MA; Manshouri, T; Keating, MJ; Kantarjian, HM; Freireich, EJ; Mehta, K; Albitar, M
      Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice

      INTERNATIONAL JOURNAL OF ONCOLOGY
    19. Huang, P; Sandoval, A; Van Den Neste, E; Keating, MJ; Plunkett, W
      Inhibition of RNA transcription: a biochemical mechanism of action againstchronic lymphocytic leukemia cells by fludarabine

      LEUKEMIA
    20. Kisor, DF; Plunkett, W; Kurtzberg, J; Mitchell, B; Hodge, JP; Ernst, T; Keating, MJ; Gandhi, V
      Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies

      JOURNAL OF CLINICAL ONCOLOGY
    21. Kantarjian, HM; O'Brien, S; Smith, TL; Cortes, J; Giles, FJ; Beran, M; Pierce, S; Huh, Y; Andreeff, M; Koller, C; Ha, CS; Keating, MJ; Murphy, S; Freireich, EJ
      Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    22. Estey, EH; Pierce, S; Keating, MJ
      Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities

      HAEMATOLOGICA
    23. Huang, P; Feng, L; Oldham, EA; Keating, MJ; Plunkett, W
      Superoxide dismutase as a target for the selective killing of cancer cells

      NATURE
    24. Tsiodras, S; Samonis, G; Keating, MJ; Kontoyiannis, DP
      Infection and immunity in chronic lymphocytic leukemia

      MAYO CLINIC PROCEEDINGS
    25. Faderl, S; Kantarjian, HM; Estey, E; Manshouri, T; Chan, CY; Elsaied, AR; Kornblau, SM; Cortes, J; Thomas, DA; Pierce, S; Keating, MJ; Estrov, Z; Albitar, M
      The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia

      CANCER
    26. Rodriguez, J; Keating, MJ; O'Brien, S; Champlin, RE; Khouri, IF
      Allogeneic haematopoietic transplantation for Richter's syndrome

      BRITISH JOURNAL OF HAEMATOLOGY
    27. Hallas, C; Albitar, M; Letofsky, J; Keating, MJ; Huebner, K; Croce, CM
      Loss of FHIT expression in acute lymphoblastic leukemia

      CLINICAL CANCER RESEARCH
    28. Kornblau, SM; Thall, PF; Estrov, Z; Walterscheid, M; Patel, S; Theriault, A; Keating, MJ; Kantarjian, H; Estey, E; Andreeff, M
      The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics

      CLINICAL CANCER RESEARCH
    29. Giles, FJ; O'Brien, SM; Santini, V; Gandhi, V; Plunkett, W; Seymour, JF; Robertson, LE; Kantarjian, HM; Keating, MJ
      Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study

      LEUKEMIA & LYMPHOMA
    30. Partyka, S; O'Brien, S; Podoloff, D; Kantarjian, H; Keating, MJ
      The usefulness of high dose (7-10mci) gallium (Ga-67) scanning to diagnoseRichter's transformation

      LEUKEMIA & LYMPHOMA
    31. Wilhelm, M; O'Brien, S; Rios, MB; Estey, E; Keating, MJ; Plunkett, W; Sorenson, M; Kantarjian, HM
      Phase I study of arabinosyl-5-azacytidine (Fazarabine) in adult acute leukemia and chronic myelogenous leukemia in elastic phase

      LEUKEMIA & LYMPHOMA
    32. Estey, EH; Thall, PF; Reed, P; Kantarjian, H; Beran, M; Pierce, S; Keating, MJ
      Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy

      LEUKEMIA
    33. Thomas, DA; Cortes, J; O'Brien, S; Pierce, S; Faderl, S; Albitar, M; Hagemeister, FB; Cabanillas, FF; Murphy, S; Keating, MJ; Kantarjian, H
      Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    34. Kantarjian, HM; O'Brien, S; Smith, TL; Rios, MB; Cortes, J; Beran, M; Koller, C; Giles, FJ; Andreeff, M; Kornblau, S; Giralt, S; Keating, MJ; Talpaz, M
      Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

      JOURNAL OF CLINICAL ONCOLOGY
    35. Keating, MJ
      Chronic lymphocytic leukemia

      SEMINARS IN ONCOLOGY
    36. Thomas, DA; Kantarjian, H; Smith, TL; Koller, C; Cortes, J; O'Brien, S; Giles, FJ; Gajewski, J; Pierce, S; Keating, MJ
      Primary refractory and relapsed adult acute lymphoblastic leukemia - Characteristics, treatment results, and prognosis with salvage therapy

      CANCER
    37. Sacchi, S; Kantarjian, HM; O'Brien, S; Cortes, J; Rios, MB; Giles, FJ; Beran, M; Koller, CA; Keating, MJ; Talpaz, M
      Chronic myelogenous leukemia in nonlymphoid blastic phase - Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

      CANCER
    38. Cortes, JE; Kantarjian, HM; O'Brien, S; Giles, F; Keating, MJ; Freireich, EJ; Estey, EH
      A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

      CANCER
    39. Aguayo, A; Cortes, JE; Kantarjian, HM; Beran, M; Gandhi, V; Plunkett, W; Kurtzberg, J; Keating, MJ
      Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase - A case report and review of the literature

      CANCER
    40. Estey, EH; Thall, PF; Pierce, S; Cortes, J; Beran, M; Kantarjian, H; Keating, MJ; Andreeff, M; Freireich, E
      Randomized phase II study of fludarabine plus cytosine arabinoside plus idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

      BLOOD
    41. KHOURI IF; KEATING MJ
      HIGH-DOSE CHEMOTHERAPY FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - ELIGIBILITY, TIMING, AND BENEFIT

      Annals of oncology
    42. SACCHI S; KANTARJIAN HM; SMITH TL; OBRIEN S; PIERCE S; KORNBLAU S; BERAN M; KEATING MJ; TALPAZ M
      EARLY TREATMENT DECISIONS WITH INTERFERON-ALPHA THERAPY IN EARLY CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    43. GANDHI V; PLUNKETT W; RODRIGUEZ CO; NOWAK BJ; DU M; AYRES M; KISOR DF; MITCHELL BS; KURTZBERG J; KEATING MJ
      COMPOUND GW506U78 IN REFRACTORY HEMATOLOGIC MALIGNANCIES - RELATIONSHIP BETWEEN CELLULAR PHARMACOKINETICS AND CLINICAL-RESPONSE

      Journal of clinical oncology
    44. BRICKLEY SG; DAWES EA; KEATING MJ; GRANT S
      SYNCHRONIZING RETINAL ACTIVITY IN BOTH EYES DISRUPTS BINOCULAR MAP DEVELOPMENT IN THE OPTIC TECTUM

      The Journal of neuroscience
    45. DELIMA M; OBRIEN S; LERNER S; KEATING MJ
      CHRONIC LYMPHOCYTIC-LEUKEMIA IN THE YOUNG PATIENT

      Seminars in oncology
    46. GILES FJ; OBRIEN SM; KEATING MJ
      CHRONIC LYMPHOCYTIC-LEUKEMIA IN (RICHTERS) TRANSFORMATION

      Seminars in oncology
    47. KEATING MJ
      CHRONIC LYMPHOCYTIC-LEUKEMIA IN THE NEXT DECADE - WHERE DO WE GO FROMHERE

      Seminars in hematology
    48. KEATING MJ; OBRIEN S; LERNER S; KOLLER C; BERAN M; ROBERTSON LE; FREIREICH EJ; ESTEY E; KANTARJIAN H
      LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC-LYMPHOCYTIC-LEUKEMIA (CLL) RECEIVING FLUDARABINE REGIMENS AS INITIAL THERAPY

      Blood
    49. ANAISSIE EJ; KONTOYIANNIS DP; OBRIEN S; KANTARJIAN H; ROBERTSON L; LERNER S; KEATING MJ
      INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA TREATED WITHFLUDARABINE

      Annals of internal medicine
    50. GANDHI V; ESTEY E; DU M; KEATING MJ; PLUNKETT W
      MINIMUM DOSE OF FLUDARABINE FOR THE MAXIMAL MODULATION OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE IN HUMAN LEUKEMIA BLASTS DURING THERAPY

      Clinical cancer research
    51. KEATING MJ
      LEUKEMIA - A MODEL FOR DRUG DEVELOPMENT

      Clinical cancer research
    52. KANTARJIAN HM; TALPAZ M; OBRIEN S; KURZROCK R; GUTTERMAN J; KEATING MJ; MCCREDIE KB; FREIREICH EJ
      CHRONIC MYELOGENOUS LEUKEMIA - PROGRESS AT THE M.-D.-ANDERSON-CANCER-CENTER OVER THE PAST 2 DECADES AND FUTURE-DIRECTIONS - FIRST FREIREICH,EMIL,J AWARD LECTURE

      Clinical cancer research
    53. RODRIGUEZ CO; LEGHA JK; ESTEY E; KEATING MJ; GANDHI V
      PHARMACOLOGICAL AND BIOCHEMICAL STRATEGIES TO INCREASE THE ACCUMULATION OF ARABINOFURANOSYLGUANINE TRIPHOSPHATE IN PRIMARY HUMAN LEUKEMIA-CELLS

      Clinical cancer research
    54. CUSACK JC; SEYMOUR JF; LERNER S; KEATING MJ; POLLOCK RE
      ROLE OF SPLENECTOMY IN CHRONIC LYMPHOCYTIC-LEUKEMIA

      Journal of the American College of Surgeons
    55. SACCHI S; KANTARJIAN HM; OBRIEN S; BERAN M; KOLLER C; PIERCE S; KORNBLAU S; ESTEY E; KEATING MJ; TALPAZ M
      LONG-TERM FOLLOW-UP RESULTS OF ALPHA-INTERFERON-BASED REGIMENS IN PATIENTS WITH LATE CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    56. OBRIEN S; KANTARJIAN H; BERAN M; KOLLER C; TALPAZ M; LERNER S; KEATING MJ
      FLUDARABINE AND GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA

      Leukemia
    57. KURZROCK R; STROM SS; ESTEY E; OBRIEN S; KEATING MJ; JIANG H; ADAMS T; TALPAZ M
      2ND CANCER RISK IN HAIRY-CELL LEUKEMIA - ANALYSIS OF 350 PATIENTS

      Journal of clinical oncology
    58. SEYMOUR JF; CUSACK JD; LERNER SA; POLLOCK RE; KEATING MJ
      CASE CONTROL STUDY OF THE ROLE OF SPLENECTOMY IN CHRONIC LYMPHOCYTIC-LEUKEMIA/

      Journal of clinical oncology
    59. HAIDAR MA; ELHAJJ H; BUESORAMOS CE; MANSHOURI T; GLASSMAN A; KEATING MJ; ALBITAR M
      EXPRESSION PROFILE OF MDM-2 PROTEINS IN CHRONIC LYMPHOCYTIC-LEUKEMIA AND THEIR CLINICAL RELEVANCE

      American journal of hematology
    60. LI L; KEATING MJ; PLUNKETT W; YANG LY
      FLUDARABINE-MEDIATED REPAIR INHIBITION OF CISPLATIN-INDUCED DNA LESIONS IN HUMAN CHRONIC MYELOGENOUS LEUKEMIA-BLAST CRISIS K562 CELLS - INDUCTION OF SYNERGISTIC CYTOTOXICITY INDEPENDENT OF REVERSAL OF APOPTOSIS RESISTANCE

      Molecular pharmacology
    61. LI L; LIU XM; GLASSMAN AB; KEATING MJ; STROS M; PLUNKETT W; YANG LY
      FLUDARABINE TRIPHOSPHATE INHIBITS NUCLEOTIDE EXCISION-REPAIR OF CISPLATIN-INDUCED DNA-ADDUCTS IN-VITRO

      Cancer research
    62. FREIREICH EJ; KEATING MJ
      INTRODUCTION TO LEUKEMIA LONG-TERM SURVIVAL

      Cancer
    63. ESTEY E; DELIMA M; STROM S; PIERCE S; FREIREICH EJ; KEATING MJ
      LONG-TERM FOLLOW-UP OF PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID-LEUKEMIA TREATED AT THE UNIVERSITY-OF-TEXAS M.-D.-ANDERSON-CANCER-CENTER

      Cancer
    64. FREIREICH EJ; KEATING MJ
      CONCLUSIONS REGARDING LEUKEMIA LONG-TERM SURVIVAL

      Cancer
    65. KHOURI IF; PRZEPIORKA D; VANBESIEN K; OBRIEN S; PALMER JL; LERNER S; MEHRA RC; VRIESENDORP HM; ANDERSSON BS; GIRALT S; KORBLING M; KEATING MJ; CHAMPLIN RE
      ALLOGENEIC BLOOD OR MARROW TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC-LEUKEMIA - TIMING OF TRANSPLANTATION AND POTENTIAL EFFECT OF FLUDARABINEON ACUTE GRAFT-VERSUS-HOST DISEASE

      British Journal of Haematology
    66. GANDHI V; RODRIGUEZ CO; KISOR DF; KEATING MJ; PLUNKETT W
      RATIONALE AND DESIGN OF PHARMACOLOGICALLY DIRECTED CLINICAL-TRIALS OFGW506U IN REFRACTORY HEMATOLOGIC MALIGNANCIES

      Blood
    67. THOMAS D; KANTARJIAN H; OBRIEN S; KEATING MJ; KOLLER C; BERAN M; ESTEY E; PIERCE S; FREIREICH E
      REFRACTORY OR RELAPSED BURKITTS TYPE ADULT LYMPHOBLASTIC-LEUKEMIA (ALL) - CHARACTERISTICS AND OUTCOME WITH SALVAGE THERAPY

      Blood
    68. THOMAS D; KANTARJIAN H; KOLLER C; OBRIEN S; KEATING MJ; BERAN M; ESTEY E; PIERCE S; FREIREICH E
      REVIEW OF 43 PATIENTS (PTS) WITH ADULT LYMPHOBLASTIC-LEUKEMIA (ALL) IN RELAPSE AFTER INITIAL CR DURATION GREATER-THAN-2 YEARS - CHARACTERISTICS, RESPONSE AND OUTCOME WITH SALVAGE THERAPY

      Blood
    69. ROMAGUERA J; KHOURI I; HAGEMEISTER FB; RODRIGUEZ MA; MCLAUGHLIN P; SARRIS A; YOUNES A; KEATING MJ; KOLLER C; OBRIEN S; RIGGS S; KANTARJIAN H; CHAMPLIN R; CABANILLAS F
      HCVAD ARA-C-MTX (HCVAD/A-M) WITH OR WITHOUT HIGH-DOSE CHEMOTHERAPY AND STEM-CELL TRANSFUSION (SCT) AS SALVAGE FOR RELAPSED OR REFRACTORY DIFFUSE/MODULAR MANTLE CELL LYMPHOMA (MCL)/

      Blood
    70. IWASAKI H; HUANG P; KEATING MJ; PLUNKETT W
      DIFFERENTIAL INCORPORATION OF ARA-C, GEMCITABINE, AND FLUDARABINE INTO REPLICATING AND REPAIRING DNA IN PROLIFERATING HUMAN LEUKEMIA-CELLS

      Blood
    71. MANSHOURI T; YANG Y; LIN H; STASS SA; GLASSMAN AB; KEATING MJ; ALBITAR M
      DOWN-REGULATION OF RAR-ALPHA IN MICE BY ANTISENSE TRANSGENE LEADS TO A COMPENSATORY INCREASE IN RAR-BETA AND RAR-GAMMA AND DEVELOPMENT OF LYMPHOMA

      Blood
    72. KEATING MJ; OBRIEN S; MCLAUGHLIN P; DIMOPOULOS M; GANDHI V; PLUNKETT W; LERNER S; KANTARJIAN H; ESTEY E
      CLINICAL-EXPERIENCE WITH FLUDARABINE IN HEMATOONCOLOGY

      HEMATOLOGY AND CELL THERAPY
    73. CRANE MM; STROM SS; HALABI S; BERMAN EL; FUEGER JJ; SPITZ MR; KEATING MJ
      CORRELATION BETWEEN SELECTED ENVIRONMENTAL EXPOSURES AND KARYOTYPE INACUTE MYELOCYTIC-LEUKEMIA

      Cancer epidemiology, biomarkers & prevention
    74. FAYAD L; ROBERTSON LE; OBRIEN S; MANNING JT; WRIGHT S; HAGEMEISTER F; CABANILLAS F; KEATING MJ
      HODGKINS-DISEASE VARIANT OF RICHTERS-SYNDROME - EXPERIENCE AT A SINGLE INSTITUTION

      Leukemia & lymphoma
    75. GHADDAR HM; PIERCE S; KANTARJIAN HM; FREIREICH EJ; KEATING MJ; ESTEY EH
      AMSACRINE AND CONTINUOUS-INFUSION HIGH-DOSE CYTOSINE-ARABINOSIDE AS INDUCTION THERAPY FOR PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA

      Leukemia & lymphoma
    76. OBRIEN S; KANTARJIAN H; KEATING MJ
      PURINE ANALOGS IN CHRONIC LYMPHOCYTIC-LEUKEMIA AND WALDENSTROMS MACROGLOBULINEMIA

      Annals of oncology
    77. ANDERLINI P; GHADDAR HM; SMITH TL; PIERCE S; KANTARJIAN HM; OBRIEN S; KEATING MJ; FREIREICH EJ; ESTEY EH
      FACTORS PREDICTING COMPLETE REMISSION AND SUBSEQUENT DISEASE-FREE SURVIVAL AFTER A 2ND COURSE OF INDUCTION THERAPY IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA RESISTANT TO THE FIRST

      Leukemia
    78. ANDERLINI P; LUNA M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; ESTEY EH
      CAUSES OF INITIAL REMISSION INDUCTION FAILURE IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

      Leukemia
    79. KANTARJIAN HM; BERAN M; OBRIEN S; ROBERTSON L; SIDDIK Z; YOSHIDA M; YANG LY; RIOS MB; KEATING MJ; MEYER M; KOWAL C; ESTEY EH
      EVALUATION OF CL-973, A PLATINUM ANALOG, IN REFRACTORY OR RELAPSED ACUTE-LEUKEMIA

      Leukemia
    80. ROBERTSON LE; PLUNKETT W; MCCONNELL K; KEATING MJ; MCDONNELL TJ
      BCL-2 EXPRESSION IN CHRONIC LYMPHOCYTIC-LEUKEMIA AND ITS CORRELATION WITH THE INDUCTION OF APOPTOSIS AND CLINICAL OUTCOME

      Leukemia
    81. WILHELM M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; FREIREICH EJ; ESTEY EH
      PNEUMONIA DURING REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS WITH AML OR MDS

      Leukemia
    82. KURTZBERG J; KEATING MJ; PLUNKETT W; GANDHI V; GOLD S; REESE M; ELION G; MITCHELL B
      COMPOUND-506 (2-AMINO-6-METHOXYPURINE ARABINOSIDE) IS ACTIVE AGAINST RESISTANT T-CELL MALIGNANCIES - PRELIMINARY-RESULTS OF AN ONGOING PHASE-I TRIAL

      Journal of clinical oncology
    83. ROBERTSON LE; DENNY AW; HUH YO; PLUNKETT W; KEATING MJ; NELSON JA
      NATURAL-KILLER-CELL ACTIVITY IN CHRONIC LYMPHOCYTIC-LEUKEMIA PATIENTSTREATED WITH FLUDARABINE

      Cancer chemotherapy and pharmacology
    84. HAIDAR MA; LOYA F; YANG Y; LIN H; GLASSMAN A; KEATING MJ; GOLDWASSER E; ALBITAR M
      DIFFERENTIAL EXPRESSION OF LACZ IN THE LIVER AND KIDNEY OF TRANSGENICMICE CARRYING CHIMERIC LACZ-ERYTHROPOIETIN GENE CONSTRUCTS WITH OR WITHOUT ITS 1.2 KB 3'-FLANKING SEQUENCE

      Nucleic acids research
    85. KHOURI I; KEATING MJ; ANDERSSON B; OBRIEN S; KORBLING M; CHAMPLIN R
      FLUDARABINE (FAMP)-BASED CHEMOTHERAPY AT CONVENTIONAL NOSES ALLOWS ENGRAFTMENT OF ALLOGENEIC (ALLO) PERIPHERAL-BLOOD, PROGENITOR-CELL (PBPC) TRANSPLANTATION IN CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)

      Experimental hematology
    86. WILHELM M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; FREIREICH EJ; ESTEY EH
      PNEUMONIA DURING REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS WITH AML OR MDS

      Blood
    87. GILES FJ; OBRIEN S; KANTARJIAN HM; PLUNKETT W; ESTEY E; BERAN M; YANG LY; SEYMOUR J; ROBERTSON LE; LERNER S; KEATING MJ
      SEQUENTIAL CISPLATINUM, FLUDARABINE, AND ARABINOSYL CYTOSINE (PFA) INPATIENTS WITH PRIOR FLUDARABINE THERAPY FOR CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) - A PHASE-II STUDY

      Blood
    88. KEATING MJ; GARSON OM; LERNER S; OBRIEN S; HAYES K; KANTARJIAN H
      LIMITED CLINICAL-SIGNIFICANCE OF CYTOGENETICS IN CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)

      Blood
    89. THOMAS D; KANTARJIAN H; KEATING MJ; OBRIEN S; PIERCE S; BERAN M; KOLLER C; FREIREICH E
      ADULT ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) IN FIRST RELAPSE - CHARACTERISTICS, OUTCOME, AND PROGNOSIS WITH SALVAGE THERAPY

      Blood
    90. GILES FJ; OBRIEN S; KANTARJIAN HM; ESTEY E; KOLLER C; PLUNKETT W; YANG LY; SEYMOUR J; ROBERTSON LE; LERNER S; KEATING MJ
      SEQUENTIAL CISPLATINUM, FLUDARABINE, AND ARABINOSYL CYTOSINE (PFA) ORCYCLOPHOSPHAMIDE, FLUDARABINE AND ARABINOSYL CYTOSINE (CFA) IN PATIENTS WITH RICHTERS-SYNDROME (RS) - A PILOT-STUDY

      Blood
    91. VANDENNESTE E; HUANG P; KEATING MJ; PLUNKETT W
      APOPTOSIS INDUCED IN CLL CELLS BY FLUDARABINE AND TRANSCRIPTIONAL INHIBITORS

      Blood
    92. KHOURI I; KEATING MJ; PRZEPIORKA D; OBRIEN S; GIRALT S; KORBLING M; CHAMPLIN R
      ENGRAFTMENT AND INDUCTION OF GVL WITH FLUDARABINE (FAMP)-BASED NON-ABLATIVE PREPARATIVE REGIMEN IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) AND LYMPHOMA

      Blood
    93. KEATING MJ; OBRIEN S; LERNER S; KOLLER C; BERAN M; KANTARJIAN H
      TREATMENT OF CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) AFTER FAILURE OR RELAPSE ON FLUDARABINE (FLU) REGIMENS (RXS)

      Blood
    94. THOMAS D; OBRIEN S; KANTARJIAN H; LERNER S; KEATING MJ
      FOLLOW-UP OF 17 PATIENTS-TREATED WITH FLUDARABINE AND PREDNISONE FOR PROGRESSIVE RAI O DISEASE IN CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL)

      Blood
    95. GANDHI V; KISOR DF; RODRIGUEZ CO; MITCHELL BS; KURTZBERG J; KEATING MJ; PLUNKETT W
      PHARMACOKINETICS OF ARABINOSYLGUANINE (ARA-G) AND ITS TRIPHOSPHATE (ARA-GTP) DURING A PHASE-I TRIAL OF COMPOUND GW506U IN REFRACTORY HEMATOLOGIC MALIGNANCIES - CORRELATION WITH RESPONSE

      Blood
    96. GANDHI V; ESTEY E; KEATING MJ; CHUCRALLAH A; PLUNKETT W
      CHLORODEOXYADENOSINE AND ARABINOSYLCYTOSINE IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA - PHARMACOKINETIC, PHARMACODYNAMIC, AND MOLECULAR-INTERACTIONS

      Blood
    97. HAN DP; VINE AK; BLODI BA; ELNER SG; JOHNSON MW; JESSUP LM; KHANDERIA S; PIERSON CL; WILLIS J; MCIVER F; STANLEY S; SNEED SR; CAPONE A; AABERG TM; LIM JI; STERNBERG P; COFFMAN DS; MOORE CN; GARDNER SK; NOLTE FS; FREMSTAD A; GIBBS D; GILMAN J; SWORDS R; AGUILAR HE; MEREDITH TA; LAKHANPAL V; CHRISTIAN FD; HOOD MA; SCHWALBE RS; BILLINGS EE; BUIE W; MALLONEE JJ; MILLAR MA; VERBEEK S; CAMPOCHIARO PA; PALARDY CB; REYNOLDS L; DICK JD; CAIN D; DAMICO DJ; FREDERICK AR; MORLEY MG; PESAVENTO RD; PULIAFITO CA; TOPPING TM; FINN SM; RAYMOND LA; BAKER AS; PATON B; EVANS C; NAPOLI J; KIERNAN C; MAKRIS K; MCINNES T; REIDY WT; WHITE R; GARFINKEL RA; PILKERTON AR; FRANTZ RA; ABERNATHY GB; BARBACCIA JG; ENSEY HR; ORMES CA; PARK CH; CAPLAN J; RUSSEL K; TOMA R; PACKO KH; DEBUSTROS S; FLOOD TP; GLAZER L; DEALBA M; EVANICH E; MONTWILL MA; ROTHMAN JJ; RUDERMAN G; BEARD M; LANDAU W; SHEN MH; GORDON M; GRAFF S; KWIATKOWSKI K; PAPPAS L; BRYANT D; DOHERTY D; MORINI F; ARREDONDO L; GARRETSON BR; GERENA C; HUNT M; KINNAIRD SM; NERI T; RICE TA; NOVAK MA; RWE PS; JAMIESON S; NEWBERRY D; RECH GR; DUL MJ; KINSER L; STROZEWSKI K; CLARKRATH S; DELISIO M; DEMPSEY DL; KUKULA D; PINTERSMITH A; ROWE PS; SMITHBREWER S; LUDWIG T; CHAMBERS RB; DAVIDORF FH; TAYLOR CS; HALE KN; BUESCHING WJ; CHAUDHURI C; COVER NJ; SHORTLIDGE GR; KEATING MJ; SAVAGE SJ; ANDRZEJEWSKA P; CORNETET S; MILLIRON JD; RICHMOND R; SCHNEIDER L; WEISENBERGER D; CANTRILL HL; RAMSAY RC; BRALLIER AB; JOHNSON TP; ROSSING EE; KNAUTH KA; MONAHAN MM; OESTREICH NW; CLARK KF; GLENNEN AM; YARIAN DL; GREEN SN; LEFF SR; MASCIULLI L; LUCIDO MM; LUDWIG EJ; MARANO CL; PETERS L; JOHO K; VOLKERT DC; ANDERSEN F; COFFEY D; SCHLOSSER A; HONEYWELL A; MAMES RN; DRIEBE WT; STERN GA; FRANCIS A; ZAM ZS; COOPER R; GASKINS D; SHAMIS DJ; WILLINGHAM M; BARKER K; ROSA H; FRIEDMAN SM; GARDNER TW; BLANKENSHIP GW; COYLE CJ; BERO CJ; HALAS C; SCHICK S; WALKER J; CUNNINGHAM D; LAMBERT HM; CLOGSTON PS; FRADY PM; GARDNER SN; OSATO MS; CARR L; SHIGLEY J; LOPEZ PF; CHONG LP; FRAMBACH DA; CISNEROS L; PADILLA M; YEE EM; NAKAMURA T; WALONKER AF; MORALES R; NICHOLS T; HUETE ME; LIGGETT PE; OBER RR; QUILLENTHOMAS B; WILLIAMS M; BARR CC; BLOOM SM; GREENE PJ; WHITTINGTON GK; MARTIN ME; WATSON G; JENKINSCURRY B; GILKEY LA; HUELSMAN S; BURTON TC; MIELER WF; PULIDO JS; REESER FH; NEWMAN JL; WERNER KA; PISARZEWICZ PJ; REINERIO NA; WALLOCH MLK; WILMER Z; LAABS J; PICCHIOTTINO R; PHILLIPS J; WIPPLINGER W; ABRAMS GW; JURKIEWICZ DT; LEET ML; MANDEL P; METZGER K; SUCHLA L; ZARLING D; BALLES MW; RYAN EH; KNOBLOCH WH; COOK SM; LUKE DG; FERRIERI P; SCHIMINSKY NM; GENIA A; PHILIPH DA; STINSON EK; WRIGHT LM; MCMICHAEL WC; MIELKE SJ; PONWITH LJ; PAVAN PR; PAUTLER SE; COATS ML; KIRK NM; MILLARD SM; CASTELLANO FC; EDWARDS CR; MARQUARDT A; MCCORMACK AJ; MCCORMICK MT; RENSHAW B; RESTUCCIA A; CAMPBELL M; CHRISTOPHER N; GARRETT LS; HALKIAS DG; HOTHERSALL K; MICKLER K; MINNICK TS; BURR C; SAXON W; ARCACHA MA; CARLTON S; EDISON SK; MALLIS MJ; SAYERS TL; SUDDS TW; TIBERIA RJ; WOLABAUGH S; BRADFORD RH; PARKE DW; WOLF TC; SHOFNER JM; TOBEY LE; JENSEN HG; SANCHEZ D; SHOFNER J; BURRIS R; DRAKE KK; GRISSOM KR; ROWSEY JJ; WILKINSON CP; BROWN GC; BENSON WE; FEDERMAN JL; LUCIER AC; MAGUIRE JI; SARIN LK; SHAKIN EP; SIVALINGAM A; TASMAN W; VANDER JF; WARD N; WEISBECKER CA; AGNEW CL; LAMBERT R; TOMER T; CARLSON K; FRANCHINE G; SERFASS MS; DOFT BH; BERGREN RL; LOBES LA; OLSEN KR; RINKOFF JS; METZ DJ; LEONARD MN; KARENCHAK LM; KOWALSKI RP; WELLMAN LA; WILCOX LA; CAMPBELL AF; STEINBERG DR; VAGSTAD GL; FLOOK KA; GOOD MM; KEENEN BJ; MELLINGER KA; MARGHERIO RR; COX MS; MURPHY PL; TRESE MT; WERNER JC; WILLIAMS GA; MANATREY PE; PROTE JL; LUCAROTTI R; MARTIN S; BAND J; BOSTIC G; CUMMING K; MITCHELL B; REGAN VS; BRIDGES C; COX S; HOUSTON G; JOHNSON J; STREASIK P; WOOD B; BLUMENKRANZ MS; CAYO L; KAYE V; VALENZUELA CL; ORGEL IK; POLINER LS; TORNAMBE PE; CANNON SV; NIELSEN JL; CARLSON A; CHAN P; DRAKE L; GRIM M; PETERSON C; BORG LA; GILLYATT J; BEYER C; HAMMER ME; GRIZZARD WS; SHANNON TL; TRAYNOM JR; COLLADO MJ; MCMANUS DW; SWEENEY DE; ADAMS DH; WATSON TT; ANTWORTH MV; ARAOS JG; GREENWALD MA; HABIB M; MYERS SK; OCKERS KM; THIBODEAU JA; WATKINS B; NELSEN PT; ROSENTHAL JG; MINTZ FV; BIEDENBACH M; LEONARDY NJ; LAWNICZAK SM; BORK C; HAGEAGE G; HUNTER EB; MARSHALL MJ; ROMAN P; HILL R; HOFBAUER T; LEMANOWICZ J; CUPPLES HP; GUZMAN GI; BRODEUR RJ; YEE D; DELAHA EC; GEYER SL; SLOVIS S; SHIELDS WJ; LAUBER S; MICHELITSCH K; BARZA M; KASSOFF A; WATLING S; WILSON LA; BUEHLER JC; MCVAY J; KELSEY SF; WISNIEWSKI SR; PODOBINSKI GK; SILLETT RL; GROER S; AVERY B; BELLE SH; BOLES J; HENRY L; SHEMA SJ; TITUSERNSTOFF L; DAVIS M; MAGLI YL; HUBBARD L; THOMAS S; EVERETT DF; MOWERY R; DAVIS K; AZEN S; COVEY P; MCCUEN B; PACKER A; ROBBIN J
      MICROBIOLOGIC FACTORS AND VISUAL OUTCOME IN THE ENDOPHTHALMITIS VITRECTOMY STUDY

      American journal of ophthalmology
    98. GANDHI V; ESTEY E; DU M; NOWAK B; KEATING MJ; PLUNKETT W
      MODULATION OF THE CELLULAR-METABOLISM OF CYTARABINE AND FLUDARABINE BY GRANULOCYTE-COLONY-STIMULATING FACTOR DURING THERAPY OF ACUTE MYELOGENOUS LEUKEMIA

      Clinical cancer research
    99. WRIGHT SJ; KEATING MJ
      CYCLOSPORINE-A IN CHRONIC LYMPHOCYTIC-LEUKEMIA - DUAL ANTILEUKEMIC AND IMMUNOSUPPRESSIVE ROLE

      Leukemia & lymphoma
    100. SEYMOUR JF; ROBERTSON LE; OBRIEN S; LERNER S; KEATING MJ
      SURVIVAL OF YOUNG-PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA FAILING FLUDARABINE THERAPY - A BASIS FOR THE USE OF MYELOABLATIVE THERAPIES

      Leukemia & lymphoma


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/06/20 alle ore 16:51:29